
Opinion|Videos|December 5, 2024
Unmet Needs in the Management of Patients with Hyperlipidemia
Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP, discusses how maximally tolerated statin therapy often fails to achieve target low-density lipoprotein cholesterol levels in high-risk patients with atherosclerotic cardiovascular disease and share strategies for optimizing adherence, including when to switch therapies to improve patient outcomes.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
- In your clinical experience, how frequently does maximally tolerated statin therapy fail to lower low-density lipoprotein cholesterol levels below 70 mg/dL in high-risk patients with atherosclerotic cardiovascular disease?
- How about levels below 55 mg/dL?
- Patient adherence to statins is often suboptimal. What are your best methods to optimize adherence?
- In which scenarios do you switch patients’ therapies to optimize adherence?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Accepts NDA for AD109 for Treatment of Adults With Obstructive Sleep Apnea
2
Pharmacists at the Forefront: Initiating, Monitoring, and Identifying Candidates for VMAT2 Therapy
3
Workforce Preparation for Fall Immunization Season Starts Now
4
Clinical Forum Events Highlight the Evolving Landscape of Obesity Management
5






































































































